GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (NAS:LUNG) » Definitions » Inventory Turnover

Pulmonx (Pulmonx) Inventory Turnover : 0.30 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Pulmonx Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Pulmonx's Cost of Goods Sold for the three months ended in Dec. 2023 was $4.88 Mil. Pulmonx's Average Total Inventories for the quarter that ended in Dec. 2023 was $16.44 Mil. Pulmonx's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.30.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Pulmonx's Days Inventory for the three months ended in Dec. 2023 was 307.48.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Pulmonx's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.85.


Pulmonx Inventory Turnover Historical Data

The historical data trend for Pulmonx's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Inventory Turnover Chart

Pulmonx Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory Turnover
Get a 7-Day Free Trial 2.28 1.41 0.95 0.89 1.14

Pulmonx Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.26 0.29 0.29 0.30

Pulmonx Inventory Turnover Calculation

Pulmonx's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Inventory Turnover (A: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2023 ) / ((Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count )
=17.923 / ((14.564 + 16.743) / 2 )
=17.923 / 15.6535
=1.14

Pulmonx's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover (Q: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Dec. 2023 ) / ((Total Inventories (Q: Sep. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count )
=4.878 / ((16.131 + 16.743) / 2 )
=4.878 / 16.437
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pulmonx  (NAS:LUNG) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Pulmonx's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory =Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=16.437/4.878*365 / 4
=307.48

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Pulmonx's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=16.437 / 19.278
=0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Pulmonx Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Pulmonx's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulmonx (Pulmonx) Business Description

Traded in Other Exchanges
Address
700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
Executives
French Glendon E. Iii director, officer: President and CEO 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Geoffrey Beran Rose officer: Chief Commercial Officer 5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016
John Mckune officer: Interim CFO 46668 CRAWFORD CT., FREMONT CA 94539
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Derrick Sung officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
Alissa Hsu Lynch director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Richard M Ferrari director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Tiffany Sullivan director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Boston Scientific Corp 10 percent owner 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel P Florin director 56 E. BELL DRIVE, WARSAW IN 46581
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Thomas William Burns director C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Georgia Melenikiotou director C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Staffan Lindstrand director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51

Pulmonx (Pulmonx) Headlines